Recombinant Human PCSK9 Protein (D374Y, His Tag)

Catalog Number: PKSH032947

Note: *Centrifuge before opening to ensure complete recovery of vial contents.*

Description

Species	Human
Source	HEK293 Cells-derived Human PCSK9 protein Gln31-Gln692(Asp374Tyr,Val474Ile, Gly504Arg,Gly670Glu), with an C-terminal His
Calculated MW	15-18&60-80 kDa
Observed MW	13.8&58.2 kDa
Accession	Q8NBP7
Bio-activity	Immobilized Recombinant Human LDL R (C-Fc) at 5μg/ml (100 μl/well) can bind Recombinant Human PCSK9 . The ED_{50} of Recombinant Human PCSK9 is 39.17 ng/ml.

Properties

Purity	＞90％ as determined by reducing SDS-PAGE.
Concentration	Subject to label value.
Endotoxin	＜1.0 EU per μg of the protein as determined by the LAL method.
Storage	Store at ＜-20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping	This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at ＜- 20°C.
Formulation	Supplied as a 0.2 μm filtered solution of 50mM HEPES, 150mM NaCl, 20% Glycerol, pH 7.4.

Data

> 90 % as determined by reducing SDS-PAGE.

Background

Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9/PCSK9 (D374Y) is a gain of function mutant of human PCSK9 protein. Human PCSK9 is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER, the pro domain and mature chain are secreted together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and it plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.

For Research Use Only